Atria Wealth Solutions Inc. Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Atria Wealth Solutions Inc. decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 51.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,254 shares of the pharmaceutical company’s stock after selling 3,402 shares during the period. Atria Wealth Solutions Inc.’s holdings in Vertex Pharmaceuticals were worth $1,452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. United Services Automobile Association purchased a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at approximately $2,933,000. Lee Johnson Capital Management LLC acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $721,000. SteelPeak Wealth LLC acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $10,059,000. Moody Lynn & Lieberson LLC raised its stake in Vertex Pharmaceuticals by 1.4% in the 2nd quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock valued at $25,856,000 after purchasing an additional 822 shares during the last quarter. Finally, New England Research & Management Inc. acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $472,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Guggenheim reduced their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Morgan Stanley reduced their price objective on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. Wells Fargo & Company raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price for the company in a research note on Wednesday, August 6th. Finally, Scotiabank cut their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $494.38.

Vertex Pharmaceuticals Stock Up 0.2%

Shares of VRTX opened at $408.61 on Friday. The company has a market capitalization of $104.76 billion, a PE ratio of 29.21 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The stock has a fifty day simple moving average of $394.46 and a two-hundred day simple moving average of $437.23.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The business had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.